Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19 : a Single-Center, Retrospective Study
Coronavirus disease (COVID-19) has spread dramatically worldwide. Nafamostat mesylate inhibits intracellular entry of the novel severe acute respiratory syndrome coronavirus 2 and is believed to have therapeutic potential for treating patients with COVID-19. In this study, patients with moderate COVID-19 who were admitted to our hospital were retrospectively analyzed. Thirty-one patients received monotherapy with nafamostat mesylate, and 33 patients were treated conservatively. Nafamostat mesylate was administered with continuous intravenous infusion for an average of 4.5 days. Compared with the conservative treatment, nafamostat mesylate did not improve outcomes or laboratory data 5 days after admission. In addition, no significant differences in laboratory data 5 days after admission and outcomes in high-risk patients were observed. The incidence of hyperkalemia was significantly higher in the nafamostat mesylate group; however, none of the patients required additional treatment. In conclusion, monotherapy with nafamostat mesylate did not improve clinical outcomes in patients with moderate COVID-19. This study did not examine the therapeutic potential of combining nafamostat mesylate with other antiviral agents, and further investigation is required. Because of the high incidence of hyperkalemia, regular laboratory monitoring is required during the use of nafamostat mesylate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Japanese journal of infectious diseases - 75(2022), 5 vom: 22. Sept., Seite 484-489 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soma, Tomomi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 23.09.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.7883/yoken.JJID.2021.699 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340200006 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340200006 | ||
| 003 | DE-627 | ||
| 005 | 20231226004614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7883/yoken.JJID.2021.699 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1133.xml |
| 035 | |a (DE-627)NLM340200006 | ||
| 035 | |a (NLM)35491224 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soma, Tomomi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19 |b a Single-Center, Retrospective Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.09.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Coronavirus disease (COVID-19) has spread dramatically worldwide. Nafamostat mesylate inhibits intracellular entry of the novel severe acute respiratory syndrome coronavirus 2 and is believed to have therapeutic potential for treating patients with COVID-19. In this study, patients with moderate COVID-19 who were admitted to our hospital were retrospectively analyzed. Thirty-one patients received monotherapy with nafamostat mesylate, and 33 patients were treated conservatively. Nafamostat mesylate was administered with continuous intravenous infusion for an average of 4.5 days. Compared with the conservative treatment, nafamostat mesylate did not improve outcomes or laboratory data 5 days after admission. In addition, no significant differences in laboratory data 5 days after admission and outcomes in high-risk patients were observed. The incidence of hyperkalemia was significantly higher in the nafamostat mesylate group; however, none of the patients required additional treatment. In conclusion, monotherapy with nafamostat mesylate did not improve clinical outcomes in patients with moderate COVID-19. This study did not examine the therapeutic potential of combining nafamostat mesylate with other antiviral agents, and further investigation is required. Because of the high incidence of hyperkalemia, regular laboratory monitoring is required during the use of nafamostat mesylate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a coronavirus disease | |
| 650 | 4 | |a hyperkalemia | |
| 650 | 4 | |a nafamostat mesylate | |
| 650 | 4 | |a single-center study | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Benzamidines |2 NLM | |
| 650 | 7 | |a Guanidines |2 NLM | |
| 650 | 7 | |a nafamostat |2 NLM | |
| 650 | 7 | |a Y25LQ0H97D |2 NLM | |
| 700 | 1 | |a Fujii, Kentaro |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshifuji, Ayumi |e verfasserin |4 aut | |
| 700 | 1 | |a Maruki, Taketomo |e verfasserin |4 aut | |
| 700 | 1 | |a Itoh, Kazuto |e verfasserin |4 aut | |
| 700 | 1 | |a Taniyama, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kikuchi, Takahide |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Morio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Japanese journal of infectious diseases |d 1999 |g 75(2022), 5 vom: 22. Sept., Seite 484-489 |w (DE-627)NLM104387572 |x 1884-2836 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2022 |g number:5 |g day:22 |g month:09 |g pages:484-489 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7883/yoken.JJID.2021.699 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2022 |e 5 |b 22 |c 09 |h 484-489 | ||